Uncategorized

Earlier this week, meta-analyses and commentary published in JAMA Internal Medicine ⎯ as part of a series on “Less is More” healthcare ⎯ asserted that most cancer screenings do not extend lifespan, thus implying little benefit to cancer screening. The authors suggest that together, previous cancer screening trials show no impact on all-cause mortality, even […]

Galleri^®, our novel multi-cancer early detection test, continues to see strong commercial progress in health systems, clinics and the employer and life insurance channels across the U.S. In the second quarter of 2023, GRAIL achieved our first 100,000 commercial Galleri test milestone. Galleri has now been prescribed by more than 7,500 providers in the U.S.,

Multi-cancer early detection (MCED) is a promising new technology to improve cancer detection rates. MCEDs are important because cancer is the second-leading killer of Americans expected to claim over 600,000 deaths this year. While MCED tests aren’t meant to replace recommended cancer screenings, the reality is there are only five cancer screening tests available in

Despite significant advancements in cancer treatment and prevention, cancer is expected to claim nearly 610,000 American lives in 2023 according to this year’s report from the American Cancer Society (ACS). The report highlighted that while overall cancer deaths are falling, death rates from some cancers and among certain at-risk populations have remained stable or have

In the first quarter of 2023, GRAIL continued to advance our mission to detect cancer early, when it can be cured. Galleri^®, a first-of-its-kind multi-cancer early detection (MCED) blood test, continues to gain traction in the cancer screening market. We are seeing strong demand from both new and existing partners and have received orders from

We like to think of an elusive “miracle cure” or “silver bullet” for cancer, but it’s more likely that truly transforming cancer today and in the foreseeable future won’t take the form of a new pill, infusion or other medical therapy. While immunotherapies and targeted treatments discovered over the last two decades have improved some

April 4, 2023 – Recently at WIRED UK Health in London, Sir Harpal Kumar, President Biopharma Business and Europe at GRAIL, gave a keynote address on the cancer landscape in the UK, the creation and history of GRAIL, and the potential impact of multi-cancer early detection on today’s cancer paradigm.  “Almost all cancers that result

Jan. 17, 2023 – A new whitepaper by Reuters Events and GRAIL highlights four health systems leading the way in implementing multi-cancer early detection (MCED) screening. The whitepaper – titled Multi-Cancer Early Detection for Health Systems: Four Adoption Models – featured expert insights from early adopters including Ochsner Health; HCA Healthcare and Sarah Cannon; Providence;

2022 was a remarkable year of growth for GRAIL, driven by the early adoption of GalleriⓇ, our multi-cancer early detection (MCED) blood test. To support the growth of the business, we more than doubled our employee base as we grew our commercial, medical and laboratory operations teams. We also added several key leadership hires to

Bob Ragusa, CEO of GRAIL 2022 was a remarkable year of growth for GRAIL, driven by early adoption of Galleri, our multi-cancer early detection (MCED) blood test. As a healthcare company with a mission to detect cancer early, when it can be cured, GRAIL seeks to improve public health by increasing the overall population cancer